mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccine

mRNA-based multi-component vaccine against SARS-CoV-2 (COVID-19) and Influenza · ModernaTX, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccine, covering 2025-12-23 to 2025-12-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults [Phase 1, Phase 2]

See pricing